Skip to content

Daniel Rosenbaum

9 papers in the library · 412 citations · publishing 2019-2025

Papers

Sort Most recent Most cited

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial

Pilot and Feasibility Studies October 28, 2025 Candice Richardson, Cindy Chan, Emily Macgregor et al. 1 citation

BACKGROUND: Individuals with advanced cancer often experience high levels of distress for which there are few standardized treatment approaches. Our multidisciplinary team has combined existing evidence-based approaches into Psilocybin-assisted Existential, Attachment, and RelationaL (PEARL) therapy. PEARL therapy combines elements from psilocybin-assisted psychotherapy, including preparatory...

The Use of Psychedelics for Grief Following Death due to Advanced Illness: A Scoping Review.

Omega July 10, 2025 Daniel Rosenbaum, Celina Carter, Brandon A Cirella et al. 1 citation

Background: There is promising evidence that psychedelic-assisted psychotherapy may be a powerful new treatment approach for mortality-related distress. However, less is known about the possible benefits for people experiencing grief. Aim: To explore what is known about using psychedelics to attend to grief following death due to advanced illness. Design: This scoping review followed Arskey and...

Experiential Training in Psychedelic-Assisted Therapy: A Risk-Benefit Analysis.

Hastings Cent Rep July 1, 2024 Daniel Rosenbaum, Crystal Hare, Emma Hapke et al. 10 citations

Well-trained, competent therapists are crucial for safe and effective psychedelic-assisted therapy (PAT). The question whether PAT training programs should require aspiring therapists to undergo their own PAT-commonly referred to as "experiential training"-has received much attention within the field. In this article, we analyze the potential benefits of experiential training in PAT by applying...

Psychedelics in PERIL: The Commercial Determinants of Health, Financial Entanglements and Population Health Ethics.

Public health ethics 2024 Daniel Z. Buchman, Daniel Rosenbaum 8 citations

The nascent for-profit psychedelic industry has begun to engage in corporate practices like funding scientific research and research programs. There is substantial evidence that such practices from other industries like tobacco, alcohol, pharmaceuticals and food create conflicts of interest and can negatively influence population health. However, in a context of funding pressures, low publicly...

Commentary: Access to Psychedelics for Psychological Suffering at the End of Life - Prioritizing Our Priorities.

Healthcare policy = Politiques de sante May 1, 2023 Daniel Rosenbaum, Sarah Hales, Daniel Z. Buchman 5 citations

We agree with Kratina et al. (2023) that the problem of psychological suffering at the end of life deserves attention from a policy standpoint and that psychedelic therapies show promise in this clinical context. However, we argue the following in this rejoinder: (1) disproportionate attention to psychedelics may overstate the current evidence base, potentially diverting resources away from...

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities

Journal of Psychopharmacology February 28, 2020 Daniel Rosenbaum, Cory R. Weissman, Thomas Anderson et al. 75 citations

Rationale: Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gaining attention in popular media but remains poorly characterized. Contemporary studies of psychedelic microdosing have yet to report the basic psychiatric descriptors of psychedelic microdosers. Objectives: To examine the practices and demographics of a...

Psychedelic microdosing benefits and challenges: an empirical codebook

Harm Reduction Journal July 9, 2019 Thomas Anderson, Rotem Petranker, Adam Christopher et al. 130 citations

These mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for future scientific research. The MDBC taxonomy reported here informs future research, leveraging participant reports to distil the highest-potential intervention targets so research funding can be efficiently allocated. Microdosing research complements...

Microdosing psychedelics: personality, mental health, and creativity differences in microdosers

Psychopharmacology January 2, 2019 Thomas Anderson, Rotem Petranker, Daniel Rosenbaum et al. 171 citations

RationaleMicrodosing psychedelics-the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin-is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include perception-distorting properties,...